In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study

This content was selected by and is provided by Sanofi.

ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission.

This selection of Meeting presentations was made by Janssen and does not necessarily represent a balanced view or full discussion of any given subject. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. The authors, editors, and ASCO are not responsible for errors or omissions in translations. The mention of any company, product, service, or therapy in this collection of materials does not constitute an endorsement of any kind by ASCO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify, among other matters, the dosage, method, and duration of administration, or contraindications. Viewers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.